Literature DB >> 25769539

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.

Anders Österborg1, Roxanne C Jewell2, Swami Padmanabhan-Iyer3, Thomas J Kipps4, Jiří Mayer5, Stephan Stilgenbauer6, Cathy D Williams7, Andrzej Hellmann8, Richard R Furman9, Tadeusz Robak10, Peter Hillmen11, Marek Trnêný12, Martin J S Dyer13, Magdalena Piotrowska14, Tomas Kozak15, Ira V Gupta16, Jennifer L Phillips16, Nancy Goldstein2, Herbert Struemper2, Nedjad Losic17, Steen Lisby17, William G Wierda18.   

Abstract

Entities:  

Keywords:  fludarabine-refractory; ofatumumab; pivotal study

Mesh：

Substances：

Year:  2015        PMID： 25769539      PMCID： PMC5004432          DOI： 10.3324/haematol.2014.121459

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

2.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

Authors:  James R Anderson; Kevin C Cain; Richard D Gelber
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

3.  Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.

Authors:  M J Keating; S O'Brien; D Kontoyiannis; W Plunkett; C Koller; M Beran; S Lerner; H Kantarjian
Journal:  Leuk Lymphoma       Date:  2002-09

4.  Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study.

Authors:  Bertrand Coiffier; Nedjad Losic; Birgitte Biilmann Rønn; Stéphane Lepretre; Lars Møller Pedersen; Ole Gadeberg; Henrik Frederiksen; Marinus H J van Oers; James Wooldridge; Janusz Kloczko; Jerzy Holowiecki; Andrzej Hellmann; Jan Walewski; Tadeusz Robak; Jørgen Petersen
Journal:  Br J Haematol       Date:  2010-04-16       Impact factor: 6.998

5.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Jirí Mayer; Stephan Stilgenbauer; Cathy D Williams; Andrzej Hellmann; Tadeusz Robak; Richard R Furman; Peter Hillmen; Marek Trneny; Martin J S Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte A Russell; Anders Osterborg
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.

Authors:  Sandra Eketorp Sylvan; Lotta Hansson; Claes Karlsson; Stefan Norin; Jeanette Lundin; Anders Osterborg
Journal:  Leuk Lymphoma       Date:  2014-02-04

7.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

8.  The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

Authors:  Constantine S Tam; Susan O'Brien; Susan Lerner; I Khouri; A Ferrajoli; S Faderl; M Browning; Apostolia M Tsimberidou; Hagop Kantarjian; William G Wierda
Journal:  Leuk Lymphoma       Date:  2007-10

9.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

10.  First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Authors:  Anton Hagenbeek; Ole Gadeberg; Peter Johnson; Lars Møller Pedersen; Jan Walewski; Andrzej Hellmann; Brian K Link; Tadeusz Robak; Marek Wojtukiewicz; Michael Pfreundschuh; Michael Kneba; Andreas Engert; Pieter Sonneveld; Mimi Flensburg; Jørgen Petersen; Nedjad Losic; John Radford
Journal:  Blood       Date:  2008-04-04       Impact factor: 22.113
View more
  5 in total

1.  Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

Authors:  Richard R Furman; Herbert A Eradat; Christine G DiRienzo; Craig C Hofmeister; Suzanne R Hayman; John P Leonard; Morton Coleman; Ranjana Advani; Asher Chanan-Khan; Julie Switzky; Qiming M Liao; Damini Shah; Roxanne C Jewell; Steen Lisby; Thomas S Lin
Journal:  Lancet Haematol       Date:  2016-12-01       Impact factor: 18.959

2.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authors:  Ian W Flinn; Peter Hillmen; Marco Montillo; Zsolt Nagy; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone J Kuss; Constantine S Tam; Zoltán Gasztonyi; Fritz Offner; Scott Lunin; Francesco Bosch; Matthew S Davids; Nicole Lamanna; Ulrich Jaeger; Paolo Ghia; Florence Cymbalista; Craig A Portell; Alan P Skarbnik; Amanda F Cashen; David T Weaver; Virginia M Kelly; Barry Turnbull; Stephan Stilgenbauer
Journal:  Blood       Date:  2018-10-04       Impact factor: 22.113

3.  Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.

Authors:  Roxanne C Jewell; Thomas J Kipps; Jan Dürig; Laimonas Griskevicius; Stephan Stilgenbauer; Lukáš Smolej; Jiří Mayer; Georg Hess; Francisco J Hernandez-Ilizaliturri; Swaminathan Padmanabhan-Iyer; Lei Fang; Nancy Goldstein; Michele Gorczyca; Ira Gupta; Steen Lisby; William G Wierda
Journal:  Leuk Lymphoma       Date:  2016-07-07

Review 4.  Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia.

Authors:  Anna Maria Frustaci; Alessandra Tedeschi; Paola Picardi; Roberto Cairoli; Marco Montillo
Journal:  Biologics       Date:  2015-09-18

Review 5.  New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.

Authors:  Luca Laurenti; Idanna Innocenti; Francesco Autore; Simona Sica; Dimitar G Efremov
Journal:  Onco Targets Ther       Date:  2016-01-20       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.